Bipartisan US Senators Reportedly Reach Breakthrough To Cap Insulin Prices at $35 – SNY, LLY, NVO Stocks Gain Pre-Market

• The bill proposes a pilot program in 10 states, allowing uninsured patients to access insulin at a capped price.
• The bill also encourages lower list prices and increasing competition from generic and biosimilar options.
• It aims to reform pharmacy benefit manager rebate systems, though funding details are not yet finalized.

A bipartisan group of U.S. senators has reportedly reached a breakthrough deal to cap insulin prices at $35, aiming to ease the financial burden for millions living with diabetes.

The proposal, led by Jeanne Shaheen and Susan Collins, now needs the backing of Senate Majority Leader John Thune and the approval of President Donald Trump, according to a Semafor report on Wednesday.

Bill Proposes Pilot Program In 10 States

The plan initially focused on insured patients, while senators John Kennedy and Raphael Warnock pushed to include uninsured individuals. As a compromise, the bill proposes a pilot program in 10 states allowing uninsured patients to access insulin at a capped price.

“I would really like to be able to leave the Senate thinking that we had helped to address insulin costs for a lot of Americans. This is the most expensive chronic disease,” Shaheen told Semafor.

According to a report by the Centers for Disease Control and Prevention in January, nearly 30 million Americans have been diagnosed with diabetes.  

The legislation also aims to cut costs by reforming pharmacy benefit manager rebate systems, though funding details are still being finalized.

Details Of The Proposal

The bipartisan bill aims to lower insulin costs and expand access for patients. The bill would extend the $35 out-of-pocket cap, currently available to Medicare users, to those with private insurance.

It also targets high insulin prices by encouraging lower list prices and increasing competition from generic and biosimilar options. In addition, the legislation ensures patients benefit directly from rebates and discounts typically handled by pharmacy benefit managers, helping reduce overall costs.

Meanwhile, shares of top insulin producers traded mixed on Wednesday. Sanofi (SNY) stock was up 2%, while shares of Eli Lilly (LLY) gained 1.5%. Novo Nordisk (NVO) shares were down 1%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.